From clinical device to consumer tool
Continuous glucose monitoring OTC refers to wearable sensors and apps that track glucose levels in real time and are available over the counter without a prescription, allowing people who are not on insulin to monitor metabolic responses to food, activity, and daily routines using phones and connected devices. This shift is changing CGM from a specialist diabetes tool into a broader wellness product. Instead of needing a prescription and clinical setup, users can buy a CGM without prescription and link it to consumer apps that display trends every few minutes. That lowers friction for people curious about their glucose patterns, from fitness enthusiasts to those managing early metabolic issues. At the same time, it raises new questions about how non‑medical users interpret data, how caregivers stay involved, and how schools or workplaces respond when health data is routed through everyday phones and wearables.
Dexcom Stelo brings OTC CGM to children
Dexcom Stelo children can now use a continuous glucose monitor without a prescription, marking a major change for pediatric metabolic tracking. The FDA cleared the Stelo Glucose Biosensor System for people aged 2 and older who do not use insulin, expanding its earlier authorization for adults. Stelo pairs a wearable sensor with an app on a compatible smartphone or smart device, including a caregiver’s phone, and displays glucose values and trends every 15 minutes. According to the FDA, Stelo is not for people who use insulin, have problematic hypoglycemia, or are on dialysis, and it does not issue low‑glucose alerts. Each sensor can last up to 15 days, though wear time may be shorter in children. Families gain an over‑the‑counter way to monitor how meals and routines affect glucose, but pediatric use still requires adult supervision and medical guidance for any treatment changes.
Ultrahuman M2 Live cuts subscriptions and prescriptions
Ultrahuman’s M2 Live platform offers continuous glucose monitoring without a prescription and with flexible pricing, pointing toward a subscription-free glucose tracker future. The service integrates with Abbott’s Lingo CGM, described as the first glucose monitor available over the counter without a prescription, and provides metabolic insights from glucose readings. Users can buy a single sensor for USD 129 (approx. RM600) or choose a USD 99 (approx. RM460) per month subscription that includes two sensors. Unlike the earlier Ultrahuman M1 Live, which cost USD 249 (approx. RM1,150) per month, M2 Live does not require any Ultrahuman hardware to function. Pairing it with the Ultrahuman Ring adds heart rate variability, sleep, and stress data for richer analysis, including a Metabolic Score from 0 to 100 and a Food Score from 0 to 10 that helps users see how different foods affect their blood glucose.
Beyond diabetes: a bigger market for metabolic tracking
Removing prescription requirements and offering a CGM without prescription subscription lock‑ins is expanding the market beyond people with insulin‑treated diabetes. Both Stelo and Ultrahuman M2 Live are cleared or positioned for adults and children who are not on insulin but want to understand glucose patterns in daily life. This includes people using oral diabetes medication, those with pre‑diabetic markers, athletes fine‑tuning performance, and wellness consumers tracking metabolic health. The trend reframes CGMs as general metabolic trackers rather than only medical devices. However, both products still include guardrails: Stelo is not intended for those with problematic hypoglycemia, and M2 Live is limited to adults not using insulin. Users are advised not to change medication based on sensor data without consulting health professionals, highlighting that over‑the‑counter access does not replace clinical care, even as it makes continuous glucose monitoring OTC far more accessible.
Schools, caregivers, and the new data layer
As children wear OTC sensors linked to phones and smart devices, schools and caregivers face new questions about policies and data response. Stelo depends on a connected workflow: a compatible smartphone, the Stelo app, and sometimes a smartwatch acting as an extension when in range of the phone. That can conflict with strict cellphone rules, limited Wi‑Fi, or device bans during exams. School IT and health staff must decide whether caregiver‑connected phones can stay nearby, how to keep apps online, and who responds if glucose data suggests a problem during class. For healthcare teams, eligibility screening remains vital, since not every child is suited for an over‑the‑counter CGM. Caregivers also need clear routines for checking readings and interpreting trends. As subscription-free glucose tracker options grow, the practical details of connectivity, supervision, and data sharing will shape how safely these tools fit into children’s daily lives.
